BRAF wild-type

P4, N=87, Shenzhen Second People's Hospital; Shenzhen Second People's Hospital

Overall, MAPK and fusion oncogenic drivers distinguish MMRd CRC molecular lineages that inform molecular and clinical phenotypes.

Amivantamab monotherapy demonstrated promising, durable antitumor activity in chemorefractory mCRC, regardless of prior anti-EGFR therapy and the primary tumor location. The amivantamab safety profile in mCRC is consistent with experience in NSCLC. Amivantamab plus chemotherapy is currently being explored in two phase III studies in first-line and second-line mCRCs.

P2/3, N=156, Recruiting, Sun Yat-sen University | Trial completion date: Dec 2028 --> Dec 2029

Of note, 6/7 cases with HER-2 mutations exhibited limited benefit from treatment with FOLFIRI plus cetuximab with PFS inferior to 8 months. Taken together, these results highlight the need to test HER-2 gene alterations for patients with RAS/BRAF V600 WT, MSS mCRC, who are candidates for anti-epidermal growth factor receptor therapies.

P=N/A, N=250, Recruiting, Niguarda Hospital

The patient was thereafter treated with a combination of pembrolizumab, nab-paclitaxel and carboplatin, resulting in a sustained near-complete response lasting over 30 months, accompanied by a manageable safety profile. The favorable response in this case suggests that further evaluation of this triplet regimen could be considered for anaplastic thyroid cancer, though this remains a speculative premise requiring validation. Further studies are also needed to clarify the underlying mechanisms of this combination and to identify predictive biomarkers for patient selection.

Patients were randomized (1:1) to FOLFIRI-cetuximab then mFOLFOX6-bevacizumab (arm A) or OPTIMOX-bevacizumab then FOLFIRI-bevacizumab followed by EGFR monoclonal antibody +/- irinotecan (arm B)...Adverse events were consistent with the well-known safety profiles. STRATEGIC-1 did not meet its primary endpoint and was inconclusive in identifying the optimal treatment strategy in wild-type RAS/BRAFV600E mCRC.

P1, N=9, Recruiting, West China Hospital | Not yet recruiting --> Recruiting

The patient was rechallenged with standard-dose IPINIVO (3: 1 mg/kg iplimumab: nivolumab) and achieved excellent clinical response despite multiple treatment-delaying toxicities: grade 2 cytokine release syndrome after cycle 1 and grade 2 pneumonitis and grade 3 colitis after cycle 2, managed with high-dose prednisone. CONCLUSIONS There are limited data on the benefit and safety of IPINIVO with rechallenge in patients who achieved initial PFS longer than 2 years, warranting further research in populations with resistant disease. Long-term safety data from rechallenge responders are needed.

P=N/A, N=140, Completed, AstraZeneca | Recruiting --> Completed | N=105 --> 140

P1, N=9, Not yet recruiting, West China Hospital